---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-015494"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T13:50:34.197572+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma issues $27,500 convertible note to GS Capital Partners

## Summary
- Entered into securities purchase agreement; note principal $27,500 at $25,000 purchase price (original issue discount).
- Note bears 8% interest (24% on default), matures October 12, 2024; conversion price initially $0.0017/share.
- Conversion price adjusts to $0.001 if stock trades below $0.0014 for 5 consecutive days; default triggers alternate fixed price.
- Company may prepay at 110-125% within 180 days; after 180 days no prepayment right.
- Note issued under Regulation D private placement; proceeds for general working capital.

## SEC filing metadata
- accession: 0001493152-24-015494
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315224015494/0001493152-24-015494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315224015494/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-015494
- JSON: https://secwatch.observer/filing/0001493152-24-015494.json
- Plain text: https://secwatch.observer/filing/0001493152-24-015494.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $27,500 with an investor at eight percent (8%) per annum maturing October 12, 2024.
  - Instrument: convertible notes
  - Principal: $27,500
  - Counterparty: an investor
  - Rate: eight percent (8%) per annum
  - Maturity: October 12, 2024
  - Event: incurrence
  source text: Effective April 16, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $27,500 (the “Note”), for a purchase price of $25,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315224015494/0001493152-24-015494-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “Investor”) valued at aggregate principal amount of $27,500 (effective 2024-04-16).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an investor (the “Investor”)
  - Value: aggregate principal amount of $27,500
  - Effective: 2024-04-16
  source text: Effective April 16, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $27,500 (the “Note”), for a purchase price of $25,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315224015494/0001493152-24-015494-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.